Search

Your search keyword '"Li, XueJing"' showing total 4 results
Start Over Author "Li, XueJing" Topic efficacy
4 results on '"Li, XueJing"'

4. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

Author

Wang, Xianying, Li, Xuejing, Qie, Suhui, Zheng, Yingying, Liu, Yang, and Liu, Guoqiang

Subjects
safety, Blood Glucose, Glycated Hemoglobin, Male, Dipeptidyl-Peptidase IV Inhibitors, type 2 diabetes mellitus, efficacy, Middle Aged, Heterocyclic Compounds, 2-Ring, Drug Administration Schedule, meta-analysis, Treatment Outcome, Diabetes Mellitus, Type 2, omarigliptin, Humans, Female, Systematic Review and Meta-Analysis, Research Article, Aged, Pyrans
Abstract

Background: The efficacy and safety of once-weekly dipeptidyl peptidase-4 inhibitor (DPP-4i) omarigliptin as monotherapy or add on to other antihyperglycemic agents (AHAs) in patients with type 2 diabetes mellitus (T2DM) is unclear. Methods: PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov were searched from the inception to January 24, 2018. Randomized controlled trials comparing omarigliptin with placebo or other AHAs in T2DM patients were included in our meta-analysis. Risk ratio (RR) and mean difference (MD) were used to evaluate the outcomes. Results: Totally, 11 trials involving 8276 patients were satisfied with our inclusion criteria. Compared with control group, omarigliptin was associated with a significantly stronger reduction in hemoglobin A1c (HbA1c) (MD 0.38%, 95% confidence interval [CI] [0.18, 0.58], P = .0002) and fasting plasma glucose (MD 0.48 mmol/L, 95% CI [0.14 mmol/L, 0.82 mmol/L], P = .006). Omarigliptin increased the number of participants who achieved HbA1c

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results